ISRCTN53844391已完成未知
Introduction of breast cancer prevention with tamoxifen for high risk premenopausal women in the UK (TAMoxifen Prevention study - TAM-P): a non-randomised study
niversity Hospital of South Manchester (UK)0 个研究点目标入组 136 人开始时间: 2012年10月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 136
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Pre-menopausal
- •2. Attends the Family History Clinic at the Nightingale & Genesis Prevention Centre
- •3. At moderate or high risk of breast cancer
- •4. Normal mammogram
- •5. Willing to use a non-hormonal form of contraception (mirena coil is permitted)
- •6. Upper Age Limit 46 years ; Lower Age Limit 33 years
排除标准
- •1. Use of coumarin type anticoagulants
- •2. Use of droperidol
- •3. Use of Bupropion
- •4. Diabetes (type I or II)
- •5. Use of hormonal contraceptives within 3 monhts of joining the study (mirena coil is permitted)
- •6. Pregnancy and breastfeeding
- •7. Prophylactic mastectomy or plans to have this procedure
- •8. Personal or family history of thromboembolism
- •9. Previous cancer in the last five years (except basal cell carcinoma or in situ cancer of the cervix)
- •10. Symptomatic gynaecological problems requiring medication
研究者
相似试验
进行中（未招募）
不适用
Preoperative treatment of breast cancer with a combination of epirubicin, docetaxel and bevacizumab. A translational trial on molecular markers and functional imaging to predict response early - PROMIXPatients diagnosed with breast cancer who are candidates for preoperative (neoadjuvant) chemotherapy due to localized primary breast cancer including inflammatory breast cancer suitable for primary medical treatment and/or regional lymph node metastases including ipsilateral supraclavicular nodes with breast cancer diagnosis confirmed by histological examination.MedDRA version: 9.1Level: LLTClassification code 10006200Term: Breast cancer stage IIMedDRA version: 9.1Level: LLTClassification code 10006201Term: Breast cancer stage IIIMedDRA version: 9.1Level: LLTClassification code 10021974Term: Inflammatory breast cancerEUCTR2007-005858-23-SEPROMIX Trial Group200
进行中（未招募）
不适用
Preventing Breast cancer through Assumption of Metformin, Diet and Physical Activity - Bremet Dietwomen affected by metabolic syndrome defined by at least three out of five metabolic factors: 1-glucose >110 mg/100 mL 2-triglycerides >150mg/100mL 3-HDL cholesterol <50 mg/100mL 4-waist circumference >88 cm) 5-hypertension SBP>130 mm Hg or DBP >85 mm HMedDRA version: 9.1Level: SOCClassification code 10038604MedDRA version: 9.1Level: SOCClassification code 10029104MedDRA version: 9.1Level: PTClassification code 10007649MedDRA version: 9.1Level: SOCClassification code 10022891EUCTR2008-006527-30-ITISTITUTO NAZIONALE PER LA CURA TUMORI
已完成
不适用
Prevention of breast cancer in high risk women by monitoring microrna expression in nipple aspirate fluid.breast carcinoma100836241000629110006232breast cancerNL-OMON44762niversitair Medisch Centrum Utrecht720
已完成
3 期
An international multi-centre study of tamoxifen vs placebo in women at increased risk of breast cancer.Prevention of Breast cancerCancer - BreastACTRN12610000134022Queen Mary University of London7,000
进行中（未招募）
3 期
Phase III, Randomized, Double Blind Trial Low Dose Tamoxifen Versus Placebo in Hormone Replacement Therapy (HRT) UsersBreast CancerNCT01579734European Institute of Oncology1,884